Arakis
www.arakis.comArakis is a subsidiary of Sosei Co. Ltd. It is a biopharmaceutical company that discovers, develops and commercialises innovative medicinal products based on established drugs and drug templates. Its chosen therapeutic areas are inflammatory disease and pain.
Arakis has four products in clinical development: AD 237 for chronic obstructive pulmonary disease (COPD) and AD 452 for rheumatoid arthritis (RA), AD 337 for fibromyalgia syndrome and AD 923 for cancer breakthrough pain (CBP). In addition, there is a preclinical pipeline of other opportunities, two exploratory developments and a number of research projects.
Arakis was founded in March 2000 and raised over £49m in three private equity funding rounds before it was bought out by Sosei in August 2005 for £106m.
Sosei. is an international biopharmaceutical with expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.
Staff
Contact details
Little Chesterford
Saffron Walden
Essex CB10 1XL, UK
Tel: +44-(0)1799-532350
Fax: +44-(0)1799-532351
